vTv Therapeutics (VTVT) Long-Term Debt Repayments (2015 - 2016)
vTv Therapeutics' (VTVT) quarterly Long-Term Debt Repayments came in at $4000.0 in Q4 2016, down 20.0% quarter-over-quarter from $5000.0 in Q3 2016.
Analysis
vTv Therapeutics (VTVT) Long-Term Debt Repayments (2015 - 2016) Analysis & Trends
vTv Therapeutics has disclosed Long-Term Debt Repayments across 2 years of filings, most recently posting $4000.0 for Q4 2016.
- In Q4 2016, Long-Term Debt Repayments changed N/A year-over-year to $4000.0; the TTM figure through Dec 2016 stood at $22000.0 (changed N/A YoY), while the FY2016 annual figure was $33000.0, down 62.92% from the prior year.
- Long-Term Debt Repayments came in at $4000.0 for Q4 2016 at vTv Therapeutics, down from $5000.0 in the prior quarter.
- In the past five years, Long-Term Debt Repayments ranged from a high of $13000.0 in Q3 2015 to a low of $4000.0 in Q4 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | - |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 2.00 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 5.00 Mn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | - |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | - |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 17.05 Mn |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | - |
| 10 | vTv Therapeutics | 413.85 Mn | 413.85 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2016 | 4,000.00 |
| Sep 30, 2016 | 5,000.00 |
| Sep 30, 2015 | 13,000.00 |